Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Neoplasms 4Carcinoma 3Vipoma 2Neoplasm Metastasis 2Intestinal Obstruction 2Carcinoma, Islet Cell 2Somatostatinoma 1Recurrence 1Prostatic Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Peritoneal Neoplasms 1Malignant Carcinoid Syndrome 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Diarrhea 1Chylous Ascites 1Chylothorax 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Ascites 1Adenoma, Islet Cell 1

Interventions

Calcium Aluminosilicate 2lanreotide 1isatuximab 1Surveys and Questionnaires 1Sulfasalazine 1Sugars 1Octreotide 1Levofloxacin 1Lapatinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Cyclophosphamide 1Colesevelam Hydrochloride 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Diarrhea × Octreotide × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡